Valneva (VALN) has entered into a development and manufacturing services agreement with AGC Biologics to support phase 2 studies of an investigational four-valent Shigella bioconjugate vaccine, AGC Biologics said Tuesday.

Under the agreement, Valneva will set up phase 2 supply based on the ability of AGC's Heidelberg site to guide complex molecules through clinical stages, AGC Biologics said.

Valneva licensed the candidate from LimmaTech Biologics, which earlier worked with AGC to establish GMP-compliant manufacturing and quality control of the vaccine's complex protein-polysaccharide conjugates for first-in-human studies, according to AGC.

Financial details were not disclosed.

Price: 7.63, Change: +0.02, Percent Change: +0.29